Skip to main content

Table 1 Timeline over the trial duration

From: UV light-mediated corneal crosslinking as (lymph)angioregressive pretreatment to promote graft survival after subsequent high-risk corneal transplantation (CrossCornealVision): protocol for a multicenter, randomized controlled trial

First patient first visit (FPFV):

Quarter (Q) IV 2023

Last patient first visit (LPFV):

Q III 2025

Last patient last visit (LPLV):

Q III 2027

End of trial:

Q IV 2027

Final study report:

Q III 2028

Back to article page

Trials

ISSN: 1745-6215